EU-India trade deal: Opportunity for India’s pharma sector

The EU-India Free Trade Agreement, concluded recently after nearly two decades of negotiation, holds the promise of reshaping global pharmaceutical trade dynamics. The pact opens the door to deeper integration of Indian industry into Europe's regulated drug market.

A MASSIVE MARKET WITH UNEVEN ACCESS

The European Union is one of the world's biggest pharmaceutical markets. In 2024, the EU exported medicines worth about 313 billion Euros and imported around 120 billion Euros, showing both strong demand and Europe's dominance in high-value, innovative drugs.


Govt estimates suggest that the combined EU pharmaceutical and medical technology market is worth nearly 570 billion Euros. This includes the entire healthcare value chain-active ingredients, finished medicines, biologics, advanced therapies, and medical devices.

Despite this scale, India's share in the EU pharmaceutical market remains small. While India is the world's largest supplier of generic medicines by volume, it accounts for only about 2-3% of the EU's pharmaceutical imports as compared to China (10-12%), Switzerland (20%), and United States (15-18%).

In 2024, India exported roughly USD 3 billion worth of pharmaceuticals to the EU. Europe absorbs about one-fifth of India's total pharmaceutical exports, making it an important market — but one where India is clearly under-represented, given its manufacturing strength.

This gap is not because Indian companies lack quality or capacity. Indian facilities already supply regulated markets like the US and Japan. The real challenges have been tariffs, long approval timelines, repeated inspections, and complex regulatory procedures across EU member states. These hurdles increase costs, delay market entry, and reduce competitiveness for Indian manufacturers.

The trade agreement directly targets these barriers. If implemented well, it could improve market access for Indian pharmaceutical and CDMO players-turning India's scale and compliance strengths into sustained participation in Europe's healthcare supply chain.

Prime Minister Narendra Modi has highlighted India's role in global health, supplying affordable vaccines during Covid-19, and showcasing the country as a reliable healthcare partner. The trade agreement can build on this, turning India's manufacturing scale and credibility into lasting participation in Europe's regulated pharmaceutical market.

WHAT THE FTA CHANGES

The agreement proposes elimination of 2-11% tariffs on pharmaceuticals and reduction of medical device duties from up to 27.5% to zero.

For complex injectables, oncology products, biosimilars, and sterile formulations, these reductions materially improve landed cost economics, often determining success in EU tenders.

IMPLICATIONS ACROSS PHARMA VALUE CHAIN

While FTA does not directly fund discovery, regulatory confidence improves India's attractiveness for early CMC development and integrated discovery-to-manufacture partnerships with EU biotechs.

Harmonisation can support faster approval of clinical supplies, better integration of Indian CROs into EU-led global trials, increased manufacture of CTM and comparators in India.

Impact will be most visible in sterile injectables, oncology, complex generics, and biosimilars; drug–device combinations; long-term hospital and govt tenders.

Even modest cost advantages, when combined with regulatory predictability, can unlock 5-7 years' supply agreements, shifting India from spot supplier to strategic partner.

STRATEGIC OPPORTUNITY IF INDIA PLAYS IT RIGHT

The EU-India FTA should be viewed not as an export stimulus, but as a structural reset. It aligns with Europe's need for resilient supply chains and India's ambition to move up the pharmaceutical value curve, from volume to value, from cost arbitrage to trust-based partnerships.

The real measure of success will not be tariff schedules, but whether India can translate regulatory access into credibility, consistency, and long-term presence in one of the world's most demanding healthcare markets.

If executed well, the agreement could mark a decisive step in India's evolution from "pharmacy of the world" to a global life-sciences manufacturing and development partner-benefiting patients, industry, and the broader economy alike.

(The writer is a US-based medical scientist)